Drugs / EBP11-F1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05965167 | May 2023 → Feb 2026 | disease of bone structure, hypoparathyroidism, osteoporosis | Entera Bio Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBP11-F1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05965167 ↗ |
| Route | Oral | “Oral tablets” NCT05965167 ↗ |